Camp4 Therapeutics (CAMP) EBIT Margin: 2023-2025
Historic EBIT Margin for Camp4 Therapeutics (CAMP) over the last 1 years, with Sep 2025 value amounting to -1,717.11%.
- Camp4 Therapeutics' EBIT Margin fell 2351711.00% to -1,717.11% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,415.39%, marking a year-over-year change of. This contributed to the annual value of -8,142.33% for FY2024, which is 668024.00% up from last year.
- Per Camp4 Therapeutics' latest filing, its EBIT Margin stood at -1,717.11% for Q3 2025, which was down 97.31% from -870.27% recorded in Q2 2025.
- Camp4 Therapeutics' 5-year EBIT Margin high stood at 21,800.00% for Q3 2024, and its period low was -3,525.14% during Q3 2023.
- Its 3-year average for EBIT Margin is 4,034.91%, with a median of -1,526.81% in 2025.
- As far as peak fluctuations go, Camp4 Therapeutics' EBIT Margin skyrocketed by 2,532,514bps in 2024, and later plummeted by 2,351,711bps in 2025.
- Over the past 3 years, Camp4 Therapeutics' EBIT Margin (Quarterly) stood at 16,236.14% in 2023, then tumbled by 1,838,860bps to -2,152.45% in 2024, then crashed by 2,351,711bps to -1,717.11% in 2025.
- Its last three reported values are -1,717.11% in Q3 2025, -870.27% for Q2 2025, and -1,526.81% during Q1 2025.